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Abstract
Background: Assessment of coronary heart disease (CHD) risk is typically based on a weighted combination of standard risk
factors. We sought to determine the extent to which a lipidomic approach based on red blood cell fatty acid (RBC-FA)
profiles could discriminate acute coronary syndrome (ACS) cases from controls, and to compare RBC-FA discrimination with
that based on standard risk factors.
Methodology/Principal Findings: RBC-FA profiles were measured in 668 ACS cases and 680 age-, race- and gender-
matched controls. Multivariable logistic regression models based on FA profiles (FA) and standard risk factors (SRF) were
developed on a random 2/3
rds derivation set and validated on the remaining 1/3
rd. The area under receiver operating
characteristic (ROC) curves (c-statistics), misclassification rates, and model calibrations were used to evaluate the individual
and combined models. The FA discriminated cases from controls better than the SRF (c=0.85 vs. 0.77, p=0.003) and the FA
profile added significantly to the standard model (c=0.88 vs. 0.77, p,0.0001). Hosmer-Lemeshow calibration was poor for
the FA model alone (p=0.01), but acceptable for both the SRF (p=0.30) and combined models (p=0.22). Misclassification
rates were 23%, 29% and 20% for FA, the SRF, and the combined models, respectively.
Conclusions/Significance: RBC-FA profiles contribute significantly to the discrimination of ACS cases, especially when
combined with standard risk factors. The utility of FA patterns in risk prediction warrants further investigation.
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Introduction
Predicting risk for coronary heart disease (CHD) remains an
inexact science. Several recent risk prediction algorithms have
been proposed, such as those from the Prospective Cardiovascular
Munster (PROCAM) study [1], the 3
rd Joint European Task
Force [Systematic Coronary Risk Evaluation (SCORE)] [2], the
Atherosclerosis Risk in Communities (ARIC) study [3], the
Reynolds Risk Score [4,5] and finally, the original and most
widely used system, the Framingham Risk Score [6,7] The latter
was designed to predict the 10-year risk for major coronary events,
and it does so with a c-statistic [area under the receiver operating
characteristic (ROC) curve] of 0.7–0.8 [3,6,7]. All of these
prediction algorithms generally include the following standard risk
factors: age, sex, total (or low-density lipoprotein) cholesterol (C),
high-density lipoprotein C (HDL-C), blood pressure, and smoking
and diabetic status. Despite the demonstrated utility of standard
factors in coronary heart disease (CHD) risk prediction, there
remains an intense interest in finding additional markers that
would improve upon this standard [8,9,10], and while a number
of putative risk factors have been tested, few have added
meaningfully [11,12].
Fatty acids (FAs) are powerful modulators of cell membrane
receptors and affect signal transduction, gene transcription, and
eicosanoid metabolism. They are present in many tissue compart-
ments, including plasma (non-esterified or esterified in triglycerides,
cholesteryl esters, or phospholipids), adipose tissue and cell
membranes. Some of these compartments (e.g., plasma triglycerides
and non-esterified FAs) are sensitive indicators of acute changes in
dietary habits and in hepatic and adipocyte function. Adipose tissue
FA composition is a long-term (months to years) reflection of dietary
habits, whereas membrane FA composition (e.g., red blood cells,
RBC) provides a more intermediate estimate (weeks). We [13] and
others [14,15,16] have reported that specific RBC FA (typically
omega-3, omega-6 or trans FAs) strongly predict CHD events.
However, the utility of other FAs that may be robust indicators and
regulators of metabolism is largely unknown. Because RBC-FA
reflect relatively recent FA intake, are highly correlated with
myocardial FA composition [17], and are not affected by acute
coronary events [15], they are ideal objective biomarkers of FA
status. We hypothesized that a RBC-FA ‘‘lipidomic’’ approach
(whichfocusonFA patternsinstead ofindividualFAs)would predict
risk for acute coronary syndromes (ACS) and add to the predictive
utility of standard CHD risk factors.
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Ethical Statement
This research was performed in accordance with the ethical
principles for medical research involving human subjects outlined
in the Declaration of Helsinki.
Selection of Cases
All consecutive patients admitted to two hospitals associated
with the University of Missouri-Kansas City School of Medicine
were prospectively screened for an ACS between March 2001and
June 2004 (Figure 1). The subjects signed a consent form that
included the following statement: ‘‘A small portion of your blood
will be frozen and stored in case future tests are developed specific
for heart attacks. If a future study were to be done, we may share
the blood with these researchers.’’ Acute myocardial infarction was
diagnosed based on the presentation of suggestive cardiac
symptoms and/or ischemic ECG changes, and a positive troponin
blood test [18]. A diagnosis of unstable angina was based on a
negative troponin test, new onset angina (,2 months) of at least
Canadian Cardiovascular Society Classification class III, pro-
longed (.20 minutes) rest angina, recent (,2 months) worsening
of angina, or angina that occurred within 2 weeks of a previous MI
[19]. Patients were excluded if a subsequent diagnostic study (e.g.
coronary angiography, nuclear or echocardiographic stress testing)
excluded symptomatic ischemic heart disease or confirmed an
alternative explanation for their presentation (e.g., esophagogas-
troduodenoscopy). Three physicians reviewed the charts of all
patients for whom diagnostic uncertainty remained and attained
consensus on the final diagnosis. With this approach, a total of
1,661 patients were included in this registry and enrolled as
described in Figure 1.
Selection of Controls
Patients having blood drawn for routine clinical testing were
recruited from blood drawing centers at Saint Luke’s Hospital
(where 88% of the cases were derived) between March 2004 to
March 2005 as outlined in Figure 1. To maximize similarity to
cases, participation was limited to men and non-pregnant women
over age 34. Patients entering the centers were passively invited (by
a sign placed on the registration desk) to participate in the study by
providing demographic and health information and then allowing
the phlebotomist to collect one additional 10 mL blood tube. The
study was approved by the Institutional Review Board of Saint
Luke’s Hospital and the Institutional Review Board of the
University of Missouri-Kansas City School of Medicine.
Figure 1. Flowchart describing recruitment of study subjects.
doi:10.1371/journal.pone.0005444.g001
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ACS patients completed a baseline interview within 24 to
72 hours of admission, and detailed information on patient
presentation, race, comorbidities, and treatments were obtained
by chart abstraction. Standard risk factors included age, sex, total-
C, HDL-C, a history of diagnosed hypertension and diabetes, and
smoking status [7]. Controls filled out a 19-item questionnaire
based on the interview forms used for the ACS patients. Although
all 7 risk factors were available for the cases, we did not have
independent evidence of a history of diabetes or hypertension. We
therefore use self-reported data.
Laboratory Methods
RBC-FA composition was measured as previously described
[13]. Briefly, RBC membranes were treated with 14% boron
trifluoride in methanol at 100uC for ten minutes. The resulting FA
methyl esters were analyzed by gas chromatography (GC) using an
Agilent 6890 (Agilent Technologies, Palo Alto, CA) equipped with
a capillary column (SP2560, 100 m., Supelco, Bellefonte, PA).
Coefficients of Variation (CVs) for high abundance FAs (.5.0
percent of total FAs) was between 0.3% and 1.0%, and for low
abundance FAs (,1.5%) it was between 1.6% and 5.8%. The
minimum detection level of the equipment was 0.01%. Serum
lipids were measured in the hospital laboratory by routine
enzymatic methods as clinically indicated within 1–2 days of
admission. (Lipids are not materially altered by an ACS event
[7,20]). Lipid levels in controls were determined in frozen plasma
samples.
Statistical Methods
768 patients diagnosed with ACS were matched one-to-one
with controls on the basis of age (5-yr windows), gender, and race
(Caucasian vs. non-Caucasian). 228 were excluded due to
incomplete information on HDL-C, total-C, self-reported hyper-
tension (HTN), self-reported diabetes mellitus (DM), age, gender,
or current smoking status (Figure 1). Two-thirds of the 1,348
subjects were randomly selected (without regard to matching or
case status) as a training dataset for model building, while the
remaining one-third was used later as a validation dataset to
estimate prediction capabilities. Although disregarding case-
control matching sacrifices power, it does not introduce bias,
and since we were developing prediction (as opposed to inference)
models, we chose the more conservative approach. The training
and validation datasets contained 445 and 223 cases, and 453 and
227 controls, respectively. We evaluated the predictive value of
RBC-FA profiles alone, the standard risk factors alone, and then
the combination. We also performed a secondary analysis
including only those individuals who were not taking statin drugs.
We used total cholesterol instead of LDL-C for two reasons. First,
since both provide equivalent predictive value in the Framingham
Risk calculation [7], they are essentially interchangeable (as would
be expected for values with a Spearman correlation of 0.91,
p,0.0001). Secondly, 3% of subjects had triglyceride levels greater
than 400 mg/dL (making LDL-C incalculable), and thus using
LDL-C would have reduced the number of subjects available for
our analysis.
Stepwise unconditional multivariable logistic regression was
used to develop prediction models with p=0.01 used to enter and
remain in the model. One model was developed using RBC-
FAs(FA), another with the 7 standard risk factors (SRF), and
another using the FAs selected in the FA model combined with the
standard risk factors (SRF+FA). Natural log transformations were
used for HDL-C and total-C to improve normality. Robust, non-
parametric 95% confidence intervals (CI) of the parameter
estimates were obtained using bootstrapping method with 10,000
replicates from the training data set for both FA models. In
addition to using the stepwise selected FAs, four pre-specified FA
metrics were also tested for their ability to add to the SRF model:
the omega-3 index (eicosapentaenoic acid (EPA)+docosahexaenoic
acid (DHA)) [21], the n-6:n-3 ratio [22], the total long-chain n-3
FAs (EPA+DHA+docosapentaenoic acid), and the proportion of
all long-chain polyunsaturated FAs that were of the n-3 class [23].
For each MLR model a single continuous variable, a risk score,
was calculated (equation 1) as the linear combination of the
parameter estimates (bi, i=0 to p) multiplied by each subject’s FA
levels (expressed as a percent of total FAs) or by the standard risk
factors (xij, j=1 to n) as follows:
riskscore~b0zb1x1jzb2x2j ...zbpxpn ð1Þ
The risk score was then used in the logit function (equation 2) to
determine the probability of case status, Pr(case). A Pr(case) .0.5
was classified as a case, otherwise as a control.
Pr case ðÞ ~
1
1ze{ riskscore ðÞ ð2Þ
Performance Metrics
Several metrics were examined to compare the performance of
the various models using the validation set [9,10,24,25,26].
Discrimination was assessed with the c-statistic (concordance
index). Positive likelihood ratios combine in one number the
sensitivity and specificity at the cut-point threshold by dividing the
proportion of true positives by the proportion of false positives.
This statistic indicates how likely it is that a case will have an
abnormal test compared to a control. Calibration was examined
using the Hosmer-Lemeshow statistic, a goodness-of-fit measure-
ment that compares predicted to observed counts of subjects by
risk score deciles. Misclassification rates were also determined.
The area under the ROC curve (c-statistic) was determined for
each model and the difference compared to the SRF alone. The
standard error (SE) for the c-statistic was computed as described
by Hanley and McNeil [27] taking into account the fact that the
areas were correlated since the same patient data were used in
each method [28].
Results
Baseline Characteristics
Due to matching on age, sex and race, there were no differences
in these attributes (Table 1). As expected, classic CHD risk factors
were generally more common among cases than controls. Twelve
of the 18 FAs differed between groups, with cases having lower
levels in 6 and higher levels in the other 6 FAs (Table 1).
Parameter estimates
Odds ratios for the 7 standard risk factors alone, FAs alone and
the combination are presented in Table 2. The only factors that
were significantly related to ACS case status were HDL-C
(OR=0.56, 95% CI 0.43 to 0.71) and smoking status
(OR=2.86, 95% CI 1.79 to 5.07; age and sex were not predictive
because they were matched variables). Stepwise selection identified
ten FAs significantly related to ACS case status comprising the
final model. Two FAs (eicosadienoic acid and trans oleic acid)
were directly related to case status, whereas the other eight were
inversely related. On a per-standard deviation basis, the 3
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were linoleic acid, stearic acid, and docosahexaenoic acid.
Model Discrimination
Using the standard risk factors, and the parameter estimates for
blood cell FAs, the ability of MLR models to discriminate cases
from controls were compared, both alone and in combination
(Table 3 and Figure 2). The FA performed better than the SRF,
with a c-statistic 8 percentage points higher (p=0.003). Adding the
FA profile to the standard risk factors significantly increased the c-
statistic of the latter by 11 percentage points (p,0.0001), whereas
the FA-profile derived c-statistic was not significantly improved by
including the standard risk factors (0.85 to 0.88, p=0.16).
Although the 10-FA profile added significantly to the standard
model, none of the simpler, pre-defined FA metrics (the omega-3
index, the total n6:n3 ratio, the long-chain n-6:n-3 ratio, and total
n-3) added significantly to SRF discrimination (c-statistics were
0.77–0.78 for all, compared to 0.77 to SRF alone). In the subgroup
Table 1. Baseline Characteristics of Cases and Controls (N=1,348).
Variable Cases (n=668) Controls (n=680) P-value*
Demographics
Caucasian 611 (91){ 624 (92) 0.84
Body mass index [kg/m
2] 29 (25, 33) { 27 (25, 31) ,0.0001
Myocardial infarction or revascularization (by history) 567 (85) 141 (21) ,0.0001
Family history of premature CHD 356 (53) 239 (36) ,0.0001
Statin use 290 (43) 258 (38) 0.04
Standard CVD Risk Factors
Age [yr] 59 (52, 70) 59 (52, 70) 0.94
Male 445 (67) 448 (66) 0.78
Hypertension (by history) 423 (63) 361 (53) 0.0001
Total cholesterol [mg/dL] 176 (148, 206) 187 (159, 217) ,0.0001
High density lipoprotein cholesterol [mg/dL] 39 (32, 48) 48 (40, 57) ,0.0001
Diabetes mellitus 156 (23) 110 (16) 0.0009
Currently smoking 237 (35) 97 (14) ,0.0001
Fatty Acids (% total FA)
saturated:
Palmitic acid 22 (21, 24) 21 (20, 23) ,0.0001
Stearic acid 14 (13, 16) 15 (14, 15) 0.86
monounsaturated:
Palmitoleic acid 1.4 (1.0, 1.9) 1.3 (1.0, 1.7) 0.21
Oleic Acid 18 (15, 20) 17 (15, 19) 0.0006
trans unsaturated:
trans Palmitoleic acid 0.42 (0.30, 0.59) 0.33 (0.23, 0.50) ,0.0001
trans Oleic acid 2.7 (2.2, 3.2) 2.4 (1.9, 2.9) ,0.0001
trans, trans linoleic acid 0.15 (0.11, 0.20) 0.15 (0.11, 0.19) 0.06
n-6 polyunsaturated:
Linoleic acid 14 (12, 16) 16 (15, 18) ,0.0001
c-Linolenic acid 0.37 (0.32, 0.42) 0.43 (0.37, 0.49) ,0.0001
Eicosadienoic acid 0.25 (0.22, 0.28) 0.25 (0.22, 0.28) 0.85
Eicosatrienoic acid 1.7 (1.5, 2.0) 1.7 (1.5, 1.9) 0.31
Arachidonic acid 14 (12, 17) 14 (12, 15) 0.13
Docosapentaenoic acid 0.61 (0.46, 0.76) 0.53 (0.41, 0.65) ,0.0001
Docosatetraenoic acid 2.7 (2.1, 3.5) 2.5 (2.0, 3.0) ,0.0001
n-3 polyunsaturated:
a-Linolenic acid 0.29 (0.21, 0.40) 0.44 (0.31, 0.60) ,0.0001
Eicosapentaenoic acid (EPA) 0.39 (0.30, 0.51) 0.53 (0.38, 0.85) ,0.0001
Docosapentaenoic acid 1.7 (1.3, 2.1) 1.8 (1.5, 2.0) ,0.0001
Docosahexaenoic acid (DHA) 2.6 (2.0, 3.6) 3.1 (2.4, 4.5) ,0.0001
*Mann-Whitney (Wilcoxon rank-sum) nonparametric test was used for continuous variables, and Chi-square test was used for categorical variables.
{n( % ) .
{Median (Inter-quartile range).
doi:10.1371/journal.pone.0005444.t001
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standard risk factors (SRF) separately and combined from the derivation set (per 1 SD; n=898).
Variable Structure
1S D( %o f
totalFAs) FA and SRF Separately FA and SRF Combined
Odds Ratio 95% CI* Est. (b) SE Odds Ratio 95% CI* Est. (b)S E
FA
Intercept - - - - 34.55 3.42 - - 7.29 2.67
Linoleic acid (n-6) C18:2 2.79 0.15 0.10 to 0.21 21.88 0.19 0.17 0.10 to 0.24 21.78 0.21
Stearic acid C18:0 1.72 0.22 0.15 to 0.30 21.50 0.17 0.22 0.14 to 0.30 21.52 0.18
Docosahexaenoic acid (n-3) C22:6 1.50 0.33 0.23 to 0.41 21.12 0.13 0.37 0.26 to 0.48 20.99 0.14
alpha Linoleic acid (n-3) C18:3 0.23 0.35 0.24 to 0.48 21.04 0.16 0.32 0.21 to 0.44 21.13 0.16
gamma Linolenic acid (n-6) C18:3 0.10 0.42 0.29 to 0.56 20.87 0.13 0.46 0.31 to 0.62 20.78 0.14
Palmitoleic acid C16:1 0.69 0.43 0.27 to 0.63 20.85 0.21 0.43 0.25 to 0.67 20.85 0.24
Arachidonic acid (n-6) C20:4 3.12 0.43 0.30 to 0.58 20.84 0.17 0.44 0.29 to 0.60 20.83 0.18
trans Palmitoleic acid trans C16:1 1.04 0.76 0.63 to 0.91 20.27 0.10 0.76 0.62 to 0.92 20.27 0.10
Eicosadienoic acid (n-6) C20:2 0.06 1.37 1.12 to 1.73 0.31 0.11 1.43 1.15 to 1.85 0.36 0.11
trans Oleic acid trans C18:1 0.84 1.37 1.06 to 1.82 0.31 0.12 1.32 1.02 to 1.78 0.27 0.12
SRF
Intercept - - - - 10.97 2.05 - - - -
Male - - 0.77 0.55 to 1.06 0.27 0.16 0.92 0.56 to 1.51 20.09 0.23
Hypertension - - 1.35 1.00 to 1.85 0.30 0.16 1.17 0.76 to 1.84 0.16 0.21
Diabetes Mellitus - - 1.10 0.74 to 1.59 0.09 0.19 0.79 0.46 to 1.31 20.24 0.26
Current Smoker - - 3.53 2.43 to 5.29 1.26 0.19 2.86 1.79 to 5.07 1.05 0.26
Age (per 10 years) - - 1.19 1.04 to 1.36 0.17 0.06 1.10 0.91 to 1.33 0.10 0.09
Total-C{ (per SD<43 mg/dL) - - 0.82 0.78 to 1.05 20.19 0.08 0.95 0.75 to 1.19 20.05 0.11
HDL-C{ (per SD<16 mg/dL) - - 0.54 0.40 to 0.59 20.62 0.09 0.56 0.43 to 0.71 20.57 0.12
*95% confidence intervals obtained using bootstrapping method with 10,000 replicates.
{Natural log transformation was modeled.
doi:10.1371/journal.pone.0005444.t002
Table 3. Diagnostic characteristics and misclassification error rates of ACS patients and controls from the validation set.
Model
# Variables
in Model
AUC
c-statistic
Hosmer-
Lemeshowp-value
Positive
Likelihood Ratio
Sensitivity
(TP)
Specificity
(1-FP) Misclassification Rates (%)
Total Cases Controls
(n=450) (n=223) (n=227)
All patients
SRF 7 0.77 0.30 2.5 0.70 0.72 29 30 28
FA 10 0.85{ 0.01 3.2 0.79 0.75 23 22 25
SRF+FA 17 0.88{ 0.22 3.8 0.83 0.78 20 18 22
Patients not on statins
(n=266) (n=126) (n=140)
SRF 7 0.81{ 0.15 2.9 0.73 0.75 26 27 25
FA 10 0.86 0.00 4.1 0.83 0.80 19 18 20
SRF+FA 17 0.891 0.01 4.6 0.85 0.81 15 18 12
SRF, standard risk factor model; FA, fatty acid model; SRF+FA, combined model.
{P=0.003.
{P,0.0002 when compared to SRF (all subjects).
1P=0.002 when compared to SRF (statin naı ¨ve subgroup).
TP, true positive; FP, false positive; AUC, area under the receiver operating characteristic curve (c-statistic).
doi:10.1371/journal.pone.0005444.t003
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improved over that in the group as a whole (0.81 vs. 0.77,
p=0.0002), but the addition of the FA profile (which had a c-
statistic of 0.86 in this subgroup) still added significantly (0.89 vs
0.81, p=0.002).
Model calibration
The only models for which calibration was acceptable (i.e.,
p.0.05) were those that included the SFR, either alone or when
combined with FAs (Table 3). The FA model failed calibration
because of the presence of 4 controls with FA-based risk scores
above the 90
th percentile, highly predictive of case status.
Model sensitivity and specificity
Since sensitivity and specificity were highest with the combined
model (Table 3), the positive likelihood ratio for the SRF+FA
model was about 50% greater than that for the SFR alone.
Model misclassification rate
The overall misclassification rate was 31% lower using the
SRF+FA compared to the SRF model (Table 3). When restricted
to cases, the SRF+FA misclassification rate was 40% lower.
Discussion
We found that a RBC-FA lipidomics approach discriminated
ACS cases from controls better than standard risk factors, and that
the combination of the latter with FAs performed even better,
increasing the c-statistic from 0.77 to 0.88. Importantly, the
superiority of the RBC-FA vs. the standard risk factor model was
not due to poor discrimination of the latter since the c-statistic was
very similar to that seen in the most recent report from the
Framingham group (0.77 in men and 0.79 in women) [6]. The
combined model was also well-calibrated. Thus, our findings
indicate that lipidomic approach based on RBC-FAs, an objective
and stable biomarker of FA intake and metabolism, adds
significantly to traditional CHD risk factor-based prediction.
The relations between risk for CHD and RBC levels of the
individual FAs included in the model generally fit well with
previous observations: inverse associations with omega-3 and
omega-6 FAs and direct associations with trans FAs. Of the ten
FAs included in the model, increasing levels of eight were inversely
associated with odds for ACS case status. These included the FAs
of both the omega-3 and omega-6 series, the monounsaturated FA
palmitoleic acid, and the saturated FA, stearic acid. These levels
reflect a mixture of diet and metabolism since the essential FAs
(omega-3 and omega-6) are strongly affected by diet whereas
palmitic and stearic, which can be synthesized de novo, reflect
metabolic processes. Direct associations were found only with
trans-oleic (or elaidic) acid and eicosadienoic acid. Associations of
increased intakes and/or in vivo levels of industrially-produced
trans FAs with CHD risk are well established [29], whereas little
information exists for eicosadienoic acid. It is known to be an
intermediate in a secondary biosynthetic pathway to arachidonic
acid from linoleic acid [30], and a potential substrate for cyclo-
oxygenase [31] but its physiological significance remains to be
defined. The FA that had the greatest impact was the omega-6 FA
linoleic acid, the most abundant essential FA in the diet. EPA, an
FA with well-established cardioprotective effects, was notably
absent from the ten. This is most likely explained by the fact that
each FA in the model had to predict independently of all other
FAs, and since EPA strongly correlated with DHA (which was in
the model; r=0.75, p,0.0001) it provided no additional
information. Several n-6 and n-3 FA-based metrics have been
proposed as risk markers in CHD including the omega-3 index
[32], the n-6:n3 ratio [22], and the Lands’ index [23]. For the
purpose of ACS case discrimination, none of these simple FA
metrics were able to add to the standard risk factors. Perhaps they
would have greater utility in predicting risk for sudden cardiac
death [33] than non-fatal ACS events.
A potential weakness of case control studies is that the exposure
of interest could be altered by the clinical event it is intended to
predict. The use of RBC-FAs is attractive in this regard as levels
remain stable for at least 4–6 weeks and are not appreciably
affected by CHD events in primate models [15] or in human
studies [34,35,36]. Thus, RBC-FA profiles provide an objective
biomarker of pre-event tissue FA levels, but this marker should be
further evaluated for ACS prediction in prospective cohorts.
Based on those criteria set forth by Vasan [8] that were
addressable with this study design (e.g. discrimination, positive
likelihood ratios, misclassification rates, etc.), FA profiles per-
formed well and show promise as a new risk marker for CHD.
Other proposed criteria such as the potential to reveal novel
disease mechanisms are also satisfied since FAs affect a variety of
metabolic and regulatory pathways linked to CHD (inflammation,
plaque instability, arrhythmic susceptibility, dyslipidemia, hyper-
tension, etc.). These may be in part mediated by alterations in the
activity of membrane-associated receptors[37]. Hence, pursuing
membrane-mediated mechanisms of disease could lead to new
interventional strategies to reduce CHD risk. In addition, some
specific membrane FAs are strongly altered by diet, and such
alterations have been shown to reduce risk for CHD [38,39].
Thus, tracking FA profiles could affect dietary and clinical
recommendations, another characteristic of a useful biomarker.
Figure 2. Discrimination between acute coronary syndrome
cases and controls was assessed in the validation set (n=450)
with receiver operating characteristic curves. Areas under the
curves (c-statistics) were compared for the standard risk factors alone
(c=0.77; broken gray line), the RBC-FA model alone (c=0.85; solid black
line), and the combined model (c=0.88; dashed black line). C-statistics
for both models including FAs were significantly greater than the
standard model but were not different from each other (Table 3;
abbreviations as in Table 1).
doi:10.1371/journal.pone.0005444.g002
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effectiveness, clinical applicability, and method standardization.
Finally, it would be important to compare the discriminatory
power of FA profiles to that of other emerging (e.g., inflammatory)
[40,41] CHD risk factors, some of which could theoretically
modulate or mediate the FA effect.
Strengths of this study include a large sample size, a rigorously-
defined ACS population, detailed FA analysis, the use of stable
biomarker of tissue FA status, use of separate derivation and
validation data sets, and a comprehensive examination of several
metrics of model utility. Potential limitations should also be
considered. It is possible that the outpatients who agreed to
participate were not truly representative of the case population.
Nevertheless, the fact that the standard risk factors predicted case-
control status very comparably to other prospective studies
suggests that control selection bias was unlikely to have materially
affected our results. Hypertension and diabetes were self-reported
in controls. Since these conditions are often under-diagnosed some
controls may have incorrectly reported normal blood pressure or
glycemia. Under-reporting by controls would help the SRF, but
not the FA, model discrimination. In addition, FA profiles have
been reported to predict the presence of vascular disease
independently of hypertension and diabetes [42]. Finally, as noted
earlier, the similar performance of the SRF model here and in
studies where these diagnoses were known suggests that the
classification was reasonable. We only evaluated non-fatal ACS
and results could differ for fatal CHD events (that are
predominantly due to arrhythmias). Finally, this study was
conducted in a single metropolitan area and included few
minorities, and further investigation is warranted in more diverse
populations.
In conclusion, an RBC-FA lipidomic approach added substan-
tially to standard risk factors for prediction of ACS. These findings
suggest that substantial, previously unrecognized biological
information may reside in membrane FA patterns. A deeper
appreciation of the mechanisms by which FAs modulate cellular
metabolism could lead to a new understanding of causes and
pathways of CHD as well as to improved clinical risk prediction
and treatment strategies.
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